A study by Medidata Solutions suggests that up to 20% of clinical trial budgets go to pay for procedures that are not directly related to trial endpoints. These additional procedures, which add up to about US$1 million per trial, add considerable complexity and could be viewed as unnecessarily increasing risk.
